Optimal rivaroxaban dose in asian patients with atrial fibrillation and normal or mildly impaired renal function

31 August 2019 (00:00 - 00:00)

Organised by:

Sign in to view the resources

About the speaker

Doctor Eue-Keun Choi

Seoul National University Hospital, Seoul (Korea (Republic of))

7 More presentations in this session

Presentation thumbnail

Men who live alone have poor anticoagulation control: results from Danish registries.

Doctor A. Nissen Bonde (Roskilde, DK)

Abstract Slides

Presentation thumbnail

Edoxaban Treatment in routiNe clinical prActice for patients with atrial fibrillation (AF) in Europe (ETNA-AF-Europe): 1-year follow-up according to body mass index

Professor T. Weiss (St. Polten, AT)

Presentation thumbnail

VTE-BLEED score predicts major bleeding in patients with atrial fibrillation

Professor E. Klok (Leiden, NL)

Presentation thumbnail

Comparative effectiveness and safety between non-VKA oral anticoagulants in non-valvular atrial fibrillation patients with differential duration of treatment: an analysis of the ARISTOPHANES study

Doctor X. Li (Princeton, US)

Abstract Slides

Presentation thumbnail

Antithrombotic challenge in the clinical dilemma of high-risk patients with atrial fibrillation: one-year result from ChiOTEAF Registry

Professor Y. Guo (Beijing, CN)

Abstract Slides

Access the full session

Session thumbnail

Poster Session 5 - Atrial fibrillation and oral anticoagulation 3

The Event

ESC Congress 2019

31 August - 4 September 2019

You may be interested in

Congress Session

Stroke prevention in clinical and subclinical atrial fibrillation

Congress Presentation

Interactive discussion and Q&A

Congress Presentation

State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope

ESC 365 is supported by

novartis

Explore sponsored resources

ESC 365 is supported by

novartis

Explore sponsored resources